Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a).
Katsiki N, Vrablik M, Banach M, Gouni-Berthold I. Katsiki N, et al. Among authors: gouni berthold i. Pharmaceuticals (Basel). 2023 Apr 12;16(4):577. doi: 10.3390/ph16040577. Pharmaceuticals (Basel). 2023. PMID: 37111334 Free PMC article. Review.
Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score".
Moulin P, Dufour R, Averna M, Arca M, Cefalù AB, Noto D, D'Erasmo L, Di Costanzo A, Marçais C, Alvarez-Sala Walther LA, Banach M, Borén J, Cramb R, Gouni-Berthold I, Hughes E, Johnson C, Pintó X, Reiner Ž, van Lennep JR, Soran H, Stefanutti C, Stroes E, Bruckert E. Moulin P, et al. Atherosclerosis. 2018 Aug;275:265-272. doi: 10.1016/j.atherosclerosis.2018.06.814. Epub 2018 Jun 18. Atherosclerosis. 2018. PMID: 29980054 Free article. Review.
Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score.
Moulin P, Dufour R, Averna M, Arca M, Cefalù AB, Noto D, D'Erasmo L, Di Costanzo A, Marçais C, Walther LAA, Banach M, Borén J, Cramb R, Gouni-Berthold I, Hughes E, Johnson C, Pintó X, Reiner Ž, van Lennep JR, Soran H, Stefanutti C, Stroes E, Bruckert E. Moulin P, et al. Data Brief. 2018 Oct 27;21:1334-1336. doi: 10.1016/j.dib.2018.10.125. eCollection 2018 Dec. Data Brief. 2018. PMID: 30456254 Free PMC article.
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study.
Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, Murphy J, Banach M, De Servi S, Gaita D, Gouni-Berthold I, Hovingh GK, Jozwiak JJ, Jukema JW, Kiss RG, Kownator S, Iversen HK, Maher V, Masana L, Parkhomenko A, Peeters A, Clifford P, Raslova K, Siostrzonek P, Romeo S, Tousoulis D, Vlachopoulos C, Vrablik M, Catapano AL, Poulter NR; DA VINCI study. Ray KK, et al. Eur J Prev Cardiol. 2021 Sep 20;28(11):1279-1289. doi: 10.1093/eurjpc/zwaa047. Eur J Prev Cardiol. 2021. PMID: 33580789
Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.
Vallejo-Vaz AJ, Bray S, Villa G, Brandts J, Kiru G, Murphy J, Banach M, De Servi S, Gaita D, Gouni-Berthold I, Kees Hovingh G, Jozwiak JJ, Jukema JW, Gabor Kiss R, Kownator S, Iversen HK, Maher V, Masana L, Parkhomenko A, Peeters A, Clifford P, Raslova K, Siostrzonek P, Romeo S, Tousoulis D, Vlachopoulos C, Vrablik M, Catapano AL, Poulter NR, Ray KK; DA VINCI Study Investigators. Vallejo-Vaz AJ, et al. Cardiovasc Drugs Ther. 2023 Oct;37(5):941-953. doi: 10.1007/s10557-022-07343-x. Epub 2022 May 14. Cardiovasc Drugs Ther. 2023. PMID: 35567726 Free PMC article.
Lipoprotein(a): current perspectives.
Gouni-Berthold I, Berthold HK. Gouni-Berthold I, et al. Curr Vasc Pharmacol. 2011 Nov;9(6):682-92. doi: 10.2174/157016111797484071. Curr Vasc Pharmacol. 2011. PMID: 21529331 Review.
173 results